

Laura Muñoz-Delgado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6615236/publications.pdf>

Version: 2024-02-01

81
papers

2,929
citations

304743

22
h-index

197818

49
g-index

82
all docs

82
docs citations

82
times ranked

7187
citing authors

#	ARTICLE	IF	CITATIONS
1	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint. <i>Neuromodulation</i> , 2022, 25, 817-828.	0.8	34
2	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	30
3	Increased Stroke Risk in Patients with Parkinson's Disease with <i>LRRK2</i> Mutations. <i>Movement Disorders</i> , 2022, 37, 225-227.	3.9	9
4	Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients. <i>Scientific Reports</i> , 2022, 12, 1330.	3.3	14
5	Lack of Association of Group A Streptococcal Infections and Onset of Tics. <i>Neurology</i> , 2022, 98, .	1.1	16
6	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120148.	0.6	13
7	Parkinson's Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Parkinson's Disease</i> , 2022, 12, 935-955.	2.8	3
8	MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. <i>Diagnostics</i> , 2022, 12, 55.	2.6	3
9	Predictors of the change in burden, strain, mood, and quality of life among caregivers of Parkinson's disease patients. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	7
10	Reply to: "Increased Stroke Risk in Patients with Parkinson's Disease with <i>LRRK2</i> Mutations" <i>Movement Disorders</i> , 2022, 37, 1119-1120.	3.9	0
11	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
12	Impaired motor cortical plasticity associated with cannabis use disorder in young adults. <i>Addiction Biology</i> , 2021, 26, e12912.	2.6	13
13	Mood in Parkinson's disease: From early to late stage disease. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 627-646.	2.7	7
14	The role of <i>RHOT1</i> and <i>RHOT2</i> genetic variation on Parkinson disease risk and onset. <i>Neurobiology of Aging</i> , 2021, 97, 144.e1-144.e3.	3.1	3
15	Association of <i>PICALM</i> with Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 118-123.	3.9	7
16	Mutational spectrum of <i>GNAL</i> , <i>THAP1</i> and <i>TOR1A</i> genes in isolated dystonia: study in a population from Spain and systematic literature review. <i>European Journal of Neurology</i> , 2021, 28, 1188-1197.	3.3	2
17	Synaptic processes and immune-related pathways implicated in Tourette syndrome. <i>Translational Psychiatry</i> , 2021, 11, 56.	4.8	31
18	<i>NR4A2</i> Mutations Can Cause Intellectual Disability and Language Impairment With Persistent Dystonia-Parkinsonism. <i>Neurology: Genetics</i> , 2021, 7, e543.	1.9	7

#	ARTICLE	IF	CITATIONS
19	3D Printing of Diffuse Low-Grade Gliomas Involving Eloquent Cortical Areas and Subcortical Functional Pathways: Technical Note. <i>World Neurosurgery</i> , 2021, 147, 164-171.e4.	1.3	11
20	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111426.	4.6	14
21	Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates With Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. <i>Clinical Nuclear Medicine</i> , 2021, 46, e296-e306.	1.3	2
22	Falls Predict Acute Hospitalization in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, , 1-20.	2.8	5
23	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Journal of Personalized Medicine</i> , 2021, 11, 626.	2.5	10
24	Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2426-2430.	3.9	36
25	In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 68-75.	2.2	16
26	Serum lipid profile among sporadic and familial forms of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 59.	5.3	15
27	Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. <i>Brain Sciences</i> , 2021, 11, 1027.	2.3	6
28	Teaching Video NeuroImages: Clues in Myoclonus Evaluation: When to Consider Sialidosis. <i>Neurology</i> , 2021, 97, 10.1212/WNL.0000000000012464.	1.1	0
29	Assessment of intellectual impairment, health-related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: Data from the iNTD registry. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1489-1502.	3.6	7
30	Investigation of gene-environment interactions in relation to tic severity. <i>Journal of Neural Transmission</i> , 2021, 128, 1757-1765.	2.8	2
31	Predictors of Loss of Functional Independence in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. <i>Diagnostics</i> , 2021, 11, 1801.	2.6	9
32	Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients. <i>Npj Parkinson's Disease</i> , 2021, 7, 78.	5.3	2
33	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
34	Clinical Practice Patterns in Tic Disorders Among Movement Disorder Society Members. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 43.	2.0	8
35	Predictors of clinically significant quality of life impairment in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 118.	5.3	17
36	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson's Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. <i>Diagnostics</i> , 2021, 11, 2380.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Short-afferent inhibition and cognitive impairment in Parkinson's disease: A quantitative review and challenges. <i>Neuroscience Letters</i> , 2020, 719, 133679.	2.1	11
38	Orthostatic Myoclonus Secondary to Central Pontine Myelinolysis. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 335-337.	1.5	1
39	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. <i>Neurological Sciences</i> , 2020, 41, 2883-2892.	1.9	13
40	Analysis of p.Tyr307Asn variant in the LRP10 gene in Parkinson's disease in southern Spain. <i>Neurobiology of Aging</i> , 2020, 93, 142.e1-142.e3.	3.1	3
41	European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 91-109.	4.7	36
42	Quantitative Intensity Harmonization of Dopamine Transporter SPECT Images Using Gamma Mixture Models. <i>Molecular Imaging and Biology</i> , 2019, 21, 339-347.	2.6	5
43	A replication study of GWAS-genetic risk variants associated with Parkinson's disease in a Spanish population. <i>Neuroscience Letters</i> , 2019, 712, 134425.	2.1	3
44	Raising serum urate levels in Parkinson disease. <i>Neurology</i> , 2019, 93, 611-612.	1.1	1
45	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
46	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.8	111
47	Abnormal cerebellar connectivity and plasticity in isolated cervical dystonia. <i>PLoS ONE</i> , 2019, 14, e0211367.	2.5	25
48	Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. <i>Journal of Parkinson's Disease</i> , 2019, 9, 173-182.	2.8	10
49	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. <i>Parkinsonism and Related Disorders</i> , 2019, 62, 196-200.	2.2	25
50	Increased bilirubin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 213-216.	2.2	18
51	In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease. <i>Brain</i> , 2018, 141, 165-176.	7.6	135
52	Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1279-1287.	3.6	19
53	Investigation of previously implicated genetic variants in chronic tic disorders: a transmission disequilibrium test approach. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 301-316.	3.2	23
54	TMEM230 in Parkinson's disease in a southern Spanish population. <i>PLoS ONE</i> , 2018, 13, e0197271.	2.5	7

#	ARTICLE	IF	CITATIONS
55	Automatic and voluntary motor inhibition: Intact processes for tic suppression?. <i>Movement Disorders</i> , 2018, 33, 1667-1669.	3.9	1
56	Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37. <i>Brain</i> , 2018, 141, 1981-1997.	7.6	40
57	Analysis of shared heritability in common disorders of the brain. <i>Science</i> , 2018, 360, .	12.6	1,085
58	Tremor stability index: a new tool for differential diagnosis in tremor syndromes. <i>Brain</i> , 2017, 140, 1977-1986.	7.6	103
59	Genetic analysis of CHCHD2 in a southern Spanish population. <i>Neurobiology of Aging</i> , 2017, 50, 169.e1-169.e2.	3.1	6
60	Abnormal sensorimotor integration correlates with cognitive profile in vascular parkinsonism. <i>Journal of the Neurological Sciences</i> , 2017, 377, 161-166.	0.6	3
61	N370S <i>GBA1</i> mutation causes lysosomal cholesterol accumulation in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1409-1422.	3.9	86
62	A Bayesian spatial model for neuroimaging data based on biologically informed basis functions. <i>NeuroImage</i> , 2017, 161, 134-148.	4.2	18
63	Screening study of TUBB4A in isolated dystonia. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 118-120.	2.2	5
64	Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). <i>Parkinson's Disease</i> , 2017, 2017, 1-8.	1.1	53
65	Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype. <i>PLoS ONE</i> , 2017, 12, e0174644.	2.5	22
66	Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0175560.	2.5	24
67	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	1.9	100
68	GBA Variants Influence Motor and Non-Motor Features of Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0167749.	2.5	91
69	Pre- and perinatal complications in relation to Tourette syndrome and co-occurring obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. <i>Journal of Psychiatric Research</i> , 2016, 82, 126-135.	3.1	36
70	Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2016, 6, 289-298.	2.2	25
71	Trait- and state-dependent cortical inhibitory deficits in bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 261-271.	1.9	9
72	COPPADIS-2015 (COhort of Patients with PARKinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66

#	ARTICLE	IF	CITATIONS
73	Low serum uric acid levels in progressive supranuclear palsy. <i>Movement Disorders</i> , 2016, 31, 402-405.	3.9	10
74	The role of mutations in COL6A3 in isolated dystonia. <i>Journal of Neurology</i> , 2016, 263, 730-734.	3.6	15
75	<i>GDNF</i> gene is associated with tourette syndrome in a family study. <i>Movement Disorders</i> , 2015, 30, 1115-1120.	3.9	11
76	Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. <i>Journal of Neurology</i> , 2015, 262, 2201-2213.	3.6	59
77	On the long-term outcome of orthostatic tremor. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1290-1291.	2.2	2
78	Parieto-motor Cortical Dysfunction in Primary Cervical Dystonia. <i>Brain Stimulation</i> , 2014, 7, 650-657.	1.6	14
79	Clinical features and neuropsychological profile in vascular parkinsonism. <i>Journal of the Neurological Sciences</i> , 2014, 345, 193-197.	0.6	15
80	Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson's disease in southern Spain. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 248-249.	2.2	6
81	Effects of Two Weeks of Cerebellar Theta Burst Stimulation in Cervical Dystonia Patients. <i>Brain Stimulation</i> , 2014, 7, 564-572.	1.6	124